Skip to main content

TransMedics Group Inc

For the period ended Jun 30, 2024. Filed Aug 1, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 1, 2024

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Operations

(In thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Revenue:
Net product revenue$71,732$42,462$133,057$76,455
Service revenue42,57310,00378,09817,564
Total revenue114,30552,465211,15594,019
Cost of revenue:
Cost of net product revenue14,4708,55828,55415,864
Cost of service revenue30,5747,16653,37812,648
Total cost of revenue45,04415,72481,93228,512
Gross profit69,26136,741129,22365,507
Operating expenses:
Research, development and clinical trials13,8588,29125,23814,162
Selling, general and administrative42,89529,35679,05654,340
Total operating expenses56,75337,647104,29468,502
Income (loss) from operations12,508(906)24,929(2,995)
Other income (expense):
Interest expense(3,623)(2,505)(7,221)(3,596)
Interest income and other income (expense)3,2682,4316,8382,986
Total other expense, net(355)(74)(383)(610)
Income (loss) before income taxes12,153(980)24,546(3,605)
(Provision) benefit for income taxes41(21)(155)(32)
Net income (loss)$12,194$(1,001)$24,391$(3,637)
Net income (loss) per share:
Basic$0.37$(0.03)$0.74$(0.11)
Diluted$0.35$(0.03)$0.70$(0.11)
Weighted average common shares outstanding:
Basic33,119,51432,545,35232,939,85232,403,597
Diluted35,288,30832,545,35234,983,60332,403,597
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.